We use cookies to help provide you with the best possible online experience. Please read our Privacy Policy for information about which cookies we use and what information we collect on our site. By continuing to use this site, you agree that we may store and access cookies on your device.
Mylan and Fujifilm Kyowa Kirin Biologics announced the U.S. Food and Drug Administration (FDA) has approved Hulio® (adalimumab-fkjp), a biosimilar to AbbVie's Humira® (adalimumab).
NHS England said Monday that it negotiated deals with drugmakers on biosimilar versions of AbbVie's Humira (adalimumab), potentially leading to annual savings of 300 million pounds